Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Phase 1

Not yet recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Biological: Aldesleukin
Biological: Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Cyclophosphamide
Procedure: Echocardiography
Drug: Fludarabine
Procedure: Leukapheresis
Procedure: Magnetic Resonance Imaging
Procedure: Mammogram
Procedure: Multigated Acquisition Scan
Procedure: Ultrasound Imaging

First Posted Date: 2023-08-14

Last Posted Date: 2024-08-28

Lead Sponsor: University of Southern California

Target Recruit Count: 20

Registration Number: NCT05989828

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Phase 1

Recruiting

Conditions: Breast Neoplasms

Interventions: Biological: Camrelizumab
Procedure: Surgery for harvesting tumor-draining lymph nodes
Drug: Nab-paclitaxel
Drug: Cyclophosphamide
Drug: Gemcitabine
Drug: Fludarabine
Biological: Tumor-draining lymph node-derived lymphocyte (LNL)
Biological: Interleukin-2
Drug: Carboplatin

First Posted Date: 2023-08-08

Last Posted Date: 2023-08-08

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 170

Registration Number: NCT05981001

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Phase 1

Recruiting

Conditions: Breast Neoplasms

Interventions: Procedure: Sentinel Lymph Node Biopsy (SLNB)
Drug: Doxorubicin
Drug: Epirubicin
Drug: Nab-paclitaxel
Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Tumor-draining lymph node-derived lymphocyte (LNL)
Biological: Interleukin-2

First Posted Date: 2023-08-08

Last Posted Date: 2023-08-08

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 196

Registration Number: NCT05981014

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy

Phase 2

Recruiting

Conditions: Breast Neoplasms

Interventions: Drug: Trilaciclib
Drug: Epirubicin
Drug: Docetaxel
Drug: Cyclophosphamide
Drug: Carboplatin
Drug: Paclitaxel
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2023-08-07

Last Posted Date: 2023-11-30

Lead Sponsor: wang shusen

Target Recruit Count: 116

Registration Number: NCT05978648

Locations: 🇨🇳
Sun-yat sen university cancer center, Guangzhou, Gangdong, China

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Phase 1

Recruiting

Conditions: Relapsed or Refractory CD19+ B-cell Lymphoma
Relapsed or Refractory Chronic Lymphocytic Leukemia
Relapsed or Refractory Small Lymphocytic Lymphoma

Interventions: Biological: TBI-2001
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-07-27

Last Posted Date: 2024-08-12

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 19

Registration Number: NCT05963217

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil

Recruiting

Conditions: Acute Lymphoid Leukemia
Minimal Residual Disease
Gene Abnormality
Chemotherapeutic Toxicity

Interventions: Drug: Prednisone
Drug: Vincristin
Drug: Daunorubicin
Drug: Peg-asparaginase
Drug: Intrathecal Suspension
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Doxorubicin

First Posted Date: 2023-07-25

Last Posted Date: 2023-09-08

Lead Sponsor: Instituto do Cancer do Estado de São Paulo

Target Recruit Count: 180

Registration Number: NCT05959720

Locations: 🇧🇷
Instituto do Cancer do Estado de Sao Paulo, São Paulo, SP, Brazil

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Withdrawn

Conditions: Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Procedure: Echocardiography
Drug: Fludarabine
Other: Fludeoxyglucose F-18
Other: Immunotherapy
Procedure: Leukapheresis
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2023-07-18

Last Posted Date: 2024-05-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT05950113

Locations: 🇺🇸
Melanie Ayala Ceja, Los Angeles, California, United States

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

Phase 1

Recruiting

Conditions: Relapsed/Refractory B-Cell Lymphoma

Interventions: Drug: FT522
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Bendamustine

First Posted Date: 2023-07-18

Last Posted Date: 2024-07-26

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 166

Registration Number: NCT05950334

Locations: 🇺🇸
Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

and more 3 locations